Nanoviricides Inc (NNVC)
$1.47
+0.06
(+4.26%)▲
Performance
- $1.40$1.47$1.47
4.76%
Downside
Day's Volatility :4.76%
Upside
0.0%
- $1.00$3.59$1.47
31.97%
Downside
52 Weeks Volatility :72.14%
Upside
59.05%
Returns
| Period | Nanoviricides Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -19.89% | 0.0% |
6 Months | 1.44% | 0.0% |
1 Year | 8.46% | 0.0% |
3 Years | -67.36% | -20.1% |
Highlights
Market Capitalization | 20.7M |
Book Value | $0.87 |
Earnings Per Share (EPS) | -0.7 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.81% |
Return On Equity TTM | -63.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -7.8M |
Diluted Eps TTM | -0.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -0.9 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 342.18%
Technicals Summary
Sell
Neutral
Buy
Nanoviricides Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nanoviricides Inc | -16.57% | 1.44% | 8.46% | -67.36% | -19.89% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nanoviricides Inc | NA | NA | 0.0 | -0.67 | -0.63 | -0.36 | NA | 0.87 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nanoviricides Inc | Buy | $20.7M | -19.89% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Insights on Nanoviricides Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.3% return, outperforming this stock by 43.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.0% return, outperforming this stock by 101.4%
Company Information
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
Organization | Nanoviricides Inc |
Employees | 7 |
CEO | Dr. Anil R. Diwan Ph.D. |
Industry | Health Technology |
Discover More
Eagle Pharmaceuticals Inc.
$1.47
+4.26%
Rumbleon Inc
$1.47
+4.26%
Olaplex Holdings, Inc.
$1.47
+4.26%
Bluebird Bio, Inc.
$1.47
+4.26%
Generation Income Properties Inc
$1.47
+4.26%
Ondas Holdings Inc
$1.47
+4.26%
Nuveen Credit Strat Incm
$1.47
+4.26%
Touchstone Climate Transition Etf
$1.47
+4.26%
Atlas Lithium Corp
$1.47
+4.26%